

### CORPORATE AND ECONOMY NEWS

- **Mahanagar Gas Q4FY21 (QoQ):** Revenue up 8% at Rs 784.04 crore Vs Rs 727.33 crore. Net profit down 2% at Rs 212.77 crore Vs Rs 217.21 crore. Ebitda at Rs 316.16 crore Vs Rs 316.72 crore. Ebitda margins at 40.3% Vs 43.5%. Recommended final dividend of Rs 14 per share.
- **Grasim Industries Q4FY21 (Standalone, QoQ):** Revenue up 19% at Rs 4,394.25 crore Vs Rs 3,696.61 crore. Net profit 34% at Rs 480.19 crore Vs Rs 357.87 crore. Ebitda up 26% at Rs 810.89 crore Vs Rs 644.52 crore. Ebitda margin at 18.5% Vs 17.4%. Recommended a dividend of Rs 5 per share and a special dividend of Rs 4 per equity share.
- **JK Paper Q4FY21 (QoQ):** Revenue up 21% at Rs 898.16 crore Vs Rs 744.88 crore. Net profit at Rs 136.07 crore Vs Rs 64.59 crore. Ebitda up 47% at Rs 228.43 crore Vs Rs 155.19 crore. Ebitda margin at 25.4% Vs 20.8%. Recommended a dividend of Rs 4 per share.
- **Balaji Amines Q4FY21 (QoQ):** Revenue up 6% at Rs 414.03 crore Vs Rs 392.12 crore. Net profit up 13% at Rs 88.80 crore Vs Rs 78.90 crore. Ebitda up 10% at Rs 128.91 crore Vs Rs 117.36 crore. Ebitda Margins at 31.1% vs 29.9%. Recommended final dividend of Rs 4 per share.
- **GMM Pfaudler:** Commenced manufacturing operations at its facility at Vatva near Ahmedabad on May 24. The new facility will enhance the company's capacity in Heavy Engineering. It is spread over 11.9 acres with seven manufacturing bays equipped to manufacture a wide range of Heavy Engineering equipment.
- **Bal Pharma:** Launched Favipiravir formulation in the Indian market, under the brand name BALflu. Favipiravir is an emerging anti-viral drug used for patients with mild to moderate Covid-19 infection. This formulation is available in tablet form with 400 mg strength.
- **Amara Raja Batteries:** Clarior to sell 1.71 crore shares for an aggregate \$174 million. The floor price fixed at Rs 746 per share.
- **Cipla:** Swiss drug major Roche and Cipla on Monday launched the first batch of antibody cocktail against covid-19 in India. The antibody cocktail — Casirivimab and Imdevimab — is priced at ₹59,750 per dose. Roche's antibody cocktail was given to the previous US president, Donald Trump, when he contracted covid-19 last year.
- **Yes Bank:** The Securities Appellate Tribunal has imposed an interim stay on a Securities and Exchange Board of India's order issued on 12 April, in which a penalty of ₹25 crore was slapped on Yes Bank, and three of its executives for allegedly not informing investors of risk factors while facilitating the sale of the AT - 1 bonds in the secondary market.
- **ITC:** The hotel division of the FMCG major ITC Hotels said that it became the first hotel chain in the world to receive the platinum level certification in infection risk management from Norway-based DNV, a global leader that aims at boosting customers' confidence in the wake of the ongoing pandemic.
- **DHFL:** The committee of creditors of DHFL has challenged the National Company Law Tribunal (NCLT) order directing the lenders to consider the offer by the debt-ridden mortgage firm's erstwhile promoter Kapil Wadhawan.
- **Bharti Airtel:** The telecom major said its network is fully ready for 5G and also announced deployment of additional spectrum in Karnataka and Tamil Nadu to boost network quality.
- **Cadila:** Zydus Cadila launched Ujvira, a drug used for treatment of breast cancer. The company has launched Trastuzumab Emtansine, the first antibody drug conjugate (ADC) biosimilar and a highly effective drug for treating both early and advanced HER2 positive breast cancer, under the brand name Ujvira, Zydus Cadila said in a statement.
- **Key Results Today:** Ajmera Realty & Infra India, Alkem Laboratories, AstraZeneca Pharma India, Bajaj Electricals, Bayer Crop Science, Emami, GATI, Indoco Remedies, Newgen Software Technologies, Thermax, VIP Industries, among others.

Source: Bloombergquint, Economic Times, Business Standard, Business Line, Times of India, Mint, Indian Express, Business Today, Indian Express, Money Control, in.investing, Cnbctv18.

### MARKET SCAN

#### INDIAN INDICES

Index	Clsq	Chg
Sensex	50652	0.22%
Nifty	15198	0.15%
Bank Nifty	34944	0.97%
IND VIX	19.13	0.26%

#### GLOBAL INDICES

DJIA	34,394	0.54%
Nasdaq	13,661	1.41%
FTSE	7,052	0.48%
CAC	6,408	0.35%
DAX	15,438	0.44%
Nikkei	28,544	0.63%
Hang Seng	28,692	0.92%

Source: in.investing.com; As on 8.00 am IST

#### SECTOR INDEX (NSE)

IT	26144	0.15%
Infra	4213	0.44%
Energy	19584	1.33%
FMCG	34573	-0.34%
Pharma	14035	0.29%
Auto	10316	0.03%
Metals	5069	-0.60%
Midcap	25584	0.67%
Nifty 500	12962	0.35%

#### DII/FII INVESTMENT (IN.CR.)

FII/FPI	585.36
DII	-707.69

#### Top Open Interest Gainers

Stock	OI Chg	Price Chg
GUJGASLTD	19%	1.77%
CONCOR	19%	8.18%
CADILAHC	18%	1.01%
CHOLAFIN	18%	-0.94%

#### Top Open Interest Losers

TORNTPOWER	-15%	-2.79%
MPHASIS	-11%	1.10%
SBIN	-11%	2.09%
AARTIIND	-10%	0.57%

#### FOREX MARKET

USDINR	72.87	0.05%
EURINR	89.09	0.15%

#### COMMODITY MARKET

Gold (\$/OZ)	1875	-0.49%
Copper(\$/lb)	4.555	0.49%
Brent (\$/Bbl)	68.57	0.29%
Silver(\$/OZ)	27.70	-0.72%

Source: in.investing.com; As on 8.00 am IST

### GLOBAL MARKETS

#### Global Market Update

U.S. stocks climbed on Monday, with both the S&P 500 and Nasdaq jumping more than 1% as a retreat in U.S. Treasury yields helped lift expensive stocks in sectors such as technology as investors attempt to gauge the path of inflation. The Dow Jones Industrial Average rose 186.14 points, or 0.54%, to 34,393.98, the S&P 500 gained 41.19 points, or 0.99%, to 4,197.05 and the Nasdaq Composite added 190.18 points, or 1.41%, to 13,661.17.

#### Crude Oil

Oil prices rose more than 3% on Monday as a demand bump fueled by COVID-19 vaccination drives gave traders optimism that the market can absorb any Iranian oil that would come on the market if Western talks with Tehran lead to the lifting of sanctions. Brent crude oil futures settled up \$2.02, or 3%, at \$68.46 a barrel, while July U.S. West Texas Intermediate ended at \$66.05 a barrel, up \$2.47, or 3.9%.

**SGX Nifty:** Trends on SGX Nifty indicate a positive opening for the index in India with a 99 points gain. The Nifty futures were trading at 15,301 on the Singaporean Exchange around 07:30 hours IST.

### TECHNICAL VIEW

#### Nifty Outlook:

Nifty opened gap up on Monday at 15211, made a high of 15256, made a low of 15145, and closed on a positive note at 15198 levels. For the day, support for the Nifty exists at 15050 and 14950 levels, whereas resistance for the Nifty stands at 15300 and 15400 levels

#### Bank Nifty Outlook:

Bank Nifty opened gap up on Monday at 34869, made a high of 35216, made a low of 34528, and closed on a positive note at 34944 levels. For the day, support for Bank Nifty exists at 34700 and 34500 levels, whereas resistance for Bank Nifty stands at 35200 and 35500 levels.

### DERIVATIVES INDICATORS

		NIFTY OPTIONS ACTIVITY (27-MAY SERIES)	
NIFTY	15197.70 (+22.40) (+0.15%)		
NIFTY MAY FUT	15202.65 (4.95 Points Premium)	CALL	15300 CE +13.57 lac Shares
NIFTY PCR - OI	1.30 (-0.08)	CALL	15400 CE +6.59 lac Shares
NIFTY OI (Total)	1.22 Cr. (+0.75%)	PUT	15200 PE +8.72 lac Shares
INDIA VIX	19.13 (+0.26%)	PUT	14950 PE +5.50 lac Shares
BANKNIFTY	34943.60 (+0.97%)		
BANKNIFTY MAY FUT	34998.10 (54.50 Points Premium)		
BANKNIFTY OI (Total)	19.45 Lakh (-2.46%)		

#### FII DERIVATIVES STATISTICS (In Cr.)

INDEX FUTURES	-370.11
INDEX OPTIONS	-674.14
STOCK FUTURES	-1790.51
STOCK OPTIONS	221.41

Securities in Ban for Trade Date 25-MAY-2021: **CANBK, BHEL, PNB.**

### Retail Research Technical & Fundamental Calls for the Month of May-2021

#### Positional Calls (For 1-3 Months)

Date	Company	Rec	Rec Price	Stop Loss	Target	Status	Net Returns%
05-Apr	HDFCBANK	Buy	1465-1475	1370	1600-1700	Open	
28-Apr	HDFCAMC	Buy	2790-2810	2600	3200	Open	
3-May	HDFCLIFE	Buy	660-666	619	720-740	Open	
11-May	RITES	Buy	237-241	218	280-290	Open	
12-May	KEC	Buy	382-385	348	450-470	Booked	8.85%
19-May	BURGERKING	Buy	141-142	129	155-160	Part Booked	4.85%
21-May	RADICO	Buy	590-595	555	650-680	Open	
24-May	KNRCON	Buy	230-232	217.5	255-265	Open	

#### Investment Idea (For Long Term)

Date	Company	Rec	Rec Price	Target	Status	Returns%
22 Dec 20	MIDHANI	Accu	187-193	239	Open	
3 Mar 21	PSPPROJECT	Accu	490-500	590	Open	
19 Mar 21	COCHINSHIP	Accu	350-360	420	Open	
22 Apr 21	GREAVESCOT	Accu	125-128	155.00	Open	

## Asit C. Mehta

INVESTMENT INTERMEDIATES LTD.

Email: [retailresearch@acm.co.in](mailto:retailresearch@acm.co.in)

Research Analyst Registration Number:

INH000002483

CIN: U65990MH1993PLC075388

An ISO 9001:2015 Certified Company

Follow us on:



Information pertaining to Asit C. Mehta Investment Intermmediates Limited (ACMIIL):

ACMIIL is a SEBI registered Stock Broker, Merchant Banker, Portfolio Manager and Depository Participant. It is also a AMFI registered Mutual Fund Distributor. It does not have any disciplinary history. Its associate/group companies are Asit C. Mehta Commodity Services Limited, Asit C. Mehta Realty Services Pvt. Ltd, Asit C. Mehta Forex Pvt. Ltd, Nucleus IT Enabled Services , Asit C. Mehta Financial Services Limited (all providing services other than stock broking,merchant banking and portfolio management services.).

#### Disclosures

ACMIIL/its associates and its Research analysts have no financial interest in the companies covered on the report. ACMIIL/its associates and Research analysts did not have actual/beneficial ownership of one per cent or more in the companies being covered at the end of month immediately preceding the date of publication of the research report. ACMIIL/its associates or Research analysts have no material conflict of interest, have not received any compensation/benefits for any reason (including investment banking/ merchant banking or brokerage services) from either the companies concerned/third parties with respect to the companies covered in the past 12 months. ACMIIL/its associates and research analysts have neither managed or co-managed any public offering of securities of the companies covered nor engaged in market making activity for the companies being covered. Further, the companies covered neither are/nor were a client during the 12 months preceding the date of the research report. Further, the Research analyst/s covering the companies covered herein have not served as an officer/director or employee of the companies being covered

#### Disclaimer:

This report is based on information that we consider reliable, but we do not represent that it is accurate or complete and it should not be relied upon such. ACMIIL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in the report. To enhance transparency we have incorporated a Disclosure of Interest Statement in this document. This should however not be treated as endorsement of the views expressed in the report.

You are also requested to refer to the disclaimer (which is deemed to be part and parcel and is applicable to this research report as well) : <http://www.investmentz.com/disclaimer>